NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $586,875 | -68.9% | 36,339 | -20.0% | 0.00% | -75.0% |
| Q2 2023 | $1,885,222 | -28.4% | 45,427 | +3.8% | 0.00% | -42.9% |
| Q1 2023 | $2,631,426 | +8.7% | 43,755 | +32.6% | 0.01% | 0.0% |
| Q4 2022 | $2,421,210 | +0.5% | 33,009 | +4.1% | 0.01% | 0.0% |
| Q3 2022 | $2,410,000 | +63.2% | 31,719 | +49.3% | 0.01% | +40.0% |
| Q2 2022 | $1,477,000 | -5.6% | 21,245 | +12.3% | 0.01% | +25.0% |
| Q1 2022 | $1,565,000 | +36.1% | 18,920 | +23.5% | 0.00% | +33.3% |
| Q4 2021 | $1,150,000 | -31.6% | 15,325 | +5.9% | 0.00% | -25.0% |
| Q3 2021 | $1,681,000 | -33.7% | 14,466 | +26.6% | 0.00% | -33.3% |
| Q2 2021 | $2,536,000 | +39.8% | 11,431 | -16.7% | 0.01% | +50.0% |
| Q1 2021 | $1,814,000 | +85.5% | 13,717 | +143.0% | 0.00% | +100.0% |
| Q4 2020 | $978,000 | +98.8% | 5,645 | +27.9% | 0.00% | +100.0% |
| Q3 2020 | $492,000 | – | 4,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
| Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
| HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
| Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
| MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
| Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
| Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
| Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
| Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |